Exabis Library
Welcome to the e-CCO Library!
DOP006: Research gaps in diet and nutrition in inflammatory bowel disease. A topical review by ECCO
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP006: Research gaps in diet and nutrition in Inflammatory Bowel Disease. A topical review by ECCO
2017
ECCO'17 Barcelona
1
DOP007: Crohn's disease exclusion diet and partial enteral nutrition (CDED+PEN) vs exclusive enteral nutrition (EEN). Microbiome changes of a randomized clinical trial (RCT) in pediatric CD: remission is associated with similar structural + functional profiles
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha resistant Inflammatory Bowel Disease
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP007: Interleukin-10 inhibits human IFN#CHR:gamma_LOWER# and IL-17-producing T helper cells indirectly by controlling antigen-presenting cell function
2016
ECCO'16 DOP
1
DOP007: Interleukin-10 inhibits human IFNγ and IL-17-producing T helper cells indirectly by controlling antigen-presenting cell function
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP008: Dietary manipulation of the healthy human and colitic murine gut microbiome by CD-TREAT diet and exclusive enteral nutrition; a proof of concept study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP008: Dietary manipulation of the healthy human and Colitic murine gut microbiome by CD-TREAT diet and exclusive enteral nutrition; a proof of concept study
2017
ECCO'17 Barcelona
1
DOP008: Human intestinal Vδ2+ T-cells acquire antigen-presenting potency upon exposure to microbial phosphoantigen: modulation by mucosal inflammation and vedolizumab therapy
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP008: Safety of adalimumab in children and adolescents with Moderate to Severe Crohn’s Disease: Interim results of the CAPE registry
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP008: Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registry
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP009: An autoimmunity-associated variant in PTPN22 protects from disease onset in mouse models of colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP009: An autoimmunity-associated variant in PTPN22 protects from disease onset in mouse models of colitis
2016
ECCO'16 DOP
1
DOP009: Choice of corticosteroids or exclusive enteral nutrition as the first induction of remission therapy does not affect disease behavior within two years of diagnosis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP009: Choice of corticosteroids or exclusive enteral nutrition as the first induction of remission therapy does not affect disease behavior within two years of diagnosis
2017
ECCO'17 Barcelona
1
DOP009: Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP009: Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for Inflammatory Bowel Disease: A multicentre consortium propensity score–matched analysis
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1